Dendritic cells (DCs) represent the most potent inducers of adaptive immune responses. Depending on their activation phenotype, DCs drive naive T cells into distinct differentiation pathways. To achieve this, DCs are present in virtually all tissues where they sample Ag and migrate to the T cell areas of lymph nodes (LNs) and spleen. Ample evidence exists demonstrating that sphingosine 1-phosphate (S1P) is an important modulator of these processes, exerting its effects by binding to the S1P receptor S1P(1) and/or S1P(3). However, published data are contradictory, in part. We show in this study that the expression pattern, as well as the regulation of the S1P receptors, differs among in vitro-generated DCs experiencing different kinds and duration of stimuli. Moreover, the influence of S1P(1) and S1P(3) on the in vivo migration of maturing DCs depends on the origin of these cells. Thus, in vitro-generated DCs require S1P(1) and S1P(3) to accomplish this, whereas skin-derived DCs migrate unhindered in the absence of S1P(3) but not when S1P(1) signaling is blocked. Migration of lamina propria DCs to the mesenteric LNs depends on S1P(1) and S1P(3). In contrast, relocation of maturing spleen-resident DCs to the T cell zone is independent of S1P(1) and S1P(3). However, intrasplenic positioning of immature DCs to the bridging channels depends on S1P(1) activity, with no noticeable contribution of S1P(3). These observations reveal a tissue-dependent contribution of S1P(3) to DC migration and suggest a fundamental role for S1P(1) for maturing DCs migrating from periphery to draining LNs.

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.1000568DOI Listing

Publication Analysis

Top Keywords

s1p1 s1p3
16
dcs
11
dendritic cells
8
sphingosine 1-phosphate
8
s1p1
8
s1p3
8
vitro-generated dcs
8
maturing dcs
8
depends s1p1
8
contribution s1p3
8

Similar Publications

In this study novel triazine-tyrosine hybrids containing thiazole or pyridine fragments were introduced as anti- Multiple Sclerosis agents. The compounds were designed according to the structure of the Sphingosine-1-phosphate receptor subtype 1 (S1P1) modulator, fingolimode. At first, docking studies was performed using crystal structures of S1P1 and Sphingosine-1-phosphate receptor subtype 3 (S1P3) to theoretically identify the selectivity of the compounds towards the S1P1 isoform.

View Article and Find Full Text PDF

Etrasimod: First Approval.

Drugs

February 2024

Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.

Article Synopsis
  • Etrasimod (VELSIPITY™) is a small-molecule medication by Pfizer, designed to modulate specific S1P receptors, aimed at treating ulcerative colitis and related inflammatory disorders.
  • It gained its first approval in the USA in October 2023 for adults with moderately to severely active ulcerative colitis and received a positive opinion from the European Medicines Agency in December 2023 for similar use in older patients.
  • Etrasimod is also being reviewed in other countries and is in clinical trials for additional conditions like Crohn's disease and various skin disorders.
View Article and Find Full Text PDF

Endometriosis is a chronic gynecological syndrome characterized by endometrial cell invasion of the extra-uterine milieu, pelvic pain and infertility. Treatment relies on either symptomatic drugs or hormonal therapies, even though the mechanism involved in the onset of endometriosis is yet to be elucidated. The signaling of sphingolipid sphingosine 1-phosphate (S1P) is profoundly dysregulated in endometriosis.

View Article and Find Full Text PDF

Sphingosine 1-Phosphate Regulates Obesity and Glucose Homeostasis.

Int J Mol Sci

January 2024

Department of General Medicine and General Internal Medicine, Graduate School of Medicine, Gifu University, 1-1 Yanagido, Gifu 501-1194, Japan.

One of the major global health and welfare issues is the treatment of obesity and associated metabolic disorders, such as type 2 diabetes mellitus and nonalcoholic fatty liver disease. Obesity, caused by the excessive accumulation of triglycerides in adipose tissues, induces adipocyte dysfunction, followed by inflammation, in adipose tissues and lipotoxicity in nonadipose tissues. Several studies have shown that obesity and glucose homeostasis are influenced by sphingolipid mediators, including ceramide and sphingosine 1-phosphate (S1P).

View Article and Find Full Text PDF

Apolipoprotein M/sphingosine 1-phosphate protects against diabetic nephropathy.

Transl Res

August 2023

Department of Clinical Laboratory Medicine and 5Laboratory of Animal Resources, Center for Disease Biology and Integrative Medicine Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Diabetic nephropathy remains a common cause of end-stage renal failure and its associated mortality around the world. Sphingosine 1-phosphate (S1P) is a multifunctional lipid mediator and binds to HDL via apolipoprotein M (ApoM). Since HDL has been reported to be epidemiologically associated with kidney disease, we attempted to investigate the involvement of the ApoM/S1P axis in the pathogenesis/progression of diabetic nephropathy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!